Methods
chronic kidney disease
KIDNEY DISEASE
The PRISE (myocardial protection with Phosphocreatine in high-RIsk cardiac SurgEry patients) study was approved by the local ethical committee and written informed consent was obtained from all patients before inclusion to the study (ClinicalTrials.gov Identifier: NCT02757443). One hundred and twenty patients aged 18 years and older scheduled for double/triple valve repair/replacement with CPB were enrolled. Exclusion criteria were emergency surgery, concomitant coronary artery bypass grafting surgery or procedure on any part of the aorta, concomitant radiofrequency/cryo- ablation procedure, concomitant left ventricular outflow tract myomectomy (Morrow procedure), chronic kidney disease of G3 and lower categories according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria (at least one of the following present for > 3 months: glomerular filtration rate ≤ 60 ml/min/1.73 m